As we determined that the knockdown of UBQLN1 inhibited CRC cells’ progression both in vitro and in vivo, Western blot was used to detect the activity of ERK1/2, a downstream effector of RAS in the MAPK pathway. The gene discussed is MAPK3; the disease is colorectal carcinoma.